- Home
- UTHR vs CR Comparison
UTHR vs CR Comparison
Compare UTHR & CR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTHR
- CR
- Stock Information
- Founded
- UTHR 1996
- CR 1855
- Country
- UTHR United States
- CR United States
- Employees
- UTHR N/A
- CR N/A
- Industry
- UTHR Biotechnology: Pharmaceutical Preparations
- CR Metal Fabrications
- Sector
- UTHR Health Care
- CR Industrials
- Exchange
- UTHR Nasdaq
- CR Nasdaq
- Market Cap
- UTHR 13.8B
- CR 11.1B
- IPO Year
- UTHR 1999
- CR N/A
- Fundamental
- Price
- UTHR $408.38
- CR $183.52
- Analyst Decision
- UTHR Strong Buy
- CR Strong Buy
- Analyst Count
- UTHR 15
- CR 5
- Target Price
- UTHR $449.13
- CR $222.20
- AVG Volume (30 Days)
- UTHR 884.7K
- CR 324.2K
- Earning Date
- UTHR 10-29-2025
- CR 10-27-2025
- Dividend Yield
- UTHR N/A
- CR 0.50%
- EPS Growth
- UTHR 17.94
- CR 44.57
- EPS
- UTHR 25.63
- CR 6.02
- Revenue
- UTHR $3,077,800,000.00
- CR $2,227,200,000.00
- Revenue This Year
- UTHR $13.89
- CR $10.55
- Revenue Next Year
- UTHR $5.68
- CR $10.78
- P/E Ratio
- UTHR $15.74
- CR $35.43
- Revenue Growth
- UTHR 17.62
- CR 18.63
- 52 Week Low
- UTHR $266.98
- CR $127.04
- 52 Week High
- UTHR $436.95
- CR $203.89
- Technical
- Relative Strength Index (RSI)
- UTHR 70.49
- CR 44.71
- Support Level
- UTHR $396.12
- CR $179.32
- Resistance Level
- UTHR $407.06
- CR $186.79
- Average True Range (ATR)
- UTHR 13.55
- CR 4.39
- MACD
- UTHR 1.60
- CR -0.27
- Stochastic Oscillator
- UTHR 79.59
- CR 31.90
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
About CR Crane Company
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and electronics, and process flow technologies. Crane generated approximately $2.1 billion in revenue in 2024.